bluebird bio Q3 2023 Earnings Report $4.08 +0.29 (+7.65%) As of 04:00 PM Eastern Earnings HistoryForecast bluebird bio EPS ResultsActual EPS-$13.20Consensus EPS -$13.80Beat/MissBeat by +$0.60One Year Ago EPS-$18.40bluebird bio Revenue ResultsActual Revenue$12.40 millionExpected Revenue$13.56 millionBeat/MissMissed by -$1.16 millionYoY Revenue Growth+17,364.80%bluebird bio Announcement DetailsQuarterQ3 2023Date11/7/2023TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingBLUE Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Remove Ads bluebird bio Earnings HeadlinesBluebird bio reports another acquisition offer for $45M upfrontMarch 28 at 9:17 PM | bizjournals.comBluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarch 28 at 6:00 PM | marketwatch.comMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. March 28, 2025 | Golden Portfolio (Ad)Bluebird bio receives non-binding bid for up to $110.5 millionMarch 28 at 6:00 PM | reuters.combluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidMarch 28 at 5:04 PM | businesswire.combluebird bio (NASDAQ:BLUE) Stock Crosses Below 200-Day Moving Average - Here's WhyMarch 28 at 3:35 AM | americanbankingnews.comSee More bluebird bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like bluebird bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bluebird bio and other key companies, straight to your email. Email Address About bluebird biobluebird bio (NASDAQ:BLUE), a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.View bluebird bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
